Supernus Pharmaceuticals plans to raise $350m through a private placement of convertible senior notes due April 2023.

The company will grant a 30-day option to initial purchasers to buy additional notes worth $52.5m.

Based in the US, Supernus is involved in the development and commercialisation of products for the treatment of central nervous system diseases.

The company plans to use the proceeds for acquisitions, or investment in complementary businesses, products and technologies, as well as for general corporate needs.

Vanda Pharmaceuticals has issued shares of its common stock in an underwritten public offering.

The underwriters will have a 30-day option to buy an additional 15% shares.

The US-based biopharmaceutical company plans to use the proceeds towards commercial, and research and development activities, as well as general corporate purposes.

The company has appointed Citigroup Global Markets, Jefferies and Stifel, Nicolaus & Company, Incorporated as joint book-running managers, and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian as legal advisor for the transaction.

PT Kimia Farma (Persero) Tbk plans to issue notes in a public offering to raise IDR6bn ($43.52m).

Due 2021, the notes carry a rate of 7.75%.

Based in Indonesia, Persero is a pharmaceutical products provider.

The company plans to use the proceeds for capital and operational expenditures and investments in company projects.

“Vanda Pharmaceuticals has issued shares of its common stock in an underwritten public offering.”

PT Indo Premier Sekuritas, PT. BNI Securities and PT Mandiri Sekuritas have been appointed as underwriters, and PT Bank Negara Indonesia Tbk has been appointed as monitoring agent for the transaction.

Korea Arlico Pharm has issued 235,000 shares priced at KRW12,000 ($11.28) a share in a private placement to raise KRW2.8bn ($2.65m).

The South Korean pharmaceutical company plans to utilise the proceeds for working capital and other financial purposes.

Valeant Pharmaceuticals International has issued 9.25% senior notes, due to mature in 2026, in a private placement to raise C$1.5bn ($.17bn).

The Canadian pharmaceutical company plans to utilise the funds to buy back an aggregate principal amount of outstanding 6.375% and 5.375% senior notes, due 2020.

Swedish pharmaceutical company Double Bond Pharmaceutical International has issued a rights offering of shares.

Each shareholder will be entitled to receive one subscription right for one share, while holders of warrants will be eligible to get subscription of one new series B share for Skr1.65 ($0.19) for each three warrants held, as part of the transaction.

French healthcare company Sanofi has issued 1.875% notes in a sixth tranche of public offering to raise €1.25bn ($1.55bn).

Due 2038, the notes can be drawn under the Euro Medium Term Note Programme.

Sanofi has simultaneously priced the public offerings of first, second, third, fourth and fifth tranche notes to raise a total of €8bn ($9.9bn).

The company plans to utilise the proceeds for general corporate purposes, as well as for the acquisition of Bioverativ and Ablynx.

Sanofi has appointed BNP Paribas, Societe Generale Corporate & Investment Banking, UniCredit Bank, Credit Agricole, Citigroup, HSBC Holdings, ING Groep NV, JPMorgan Chase & Co, Royal Bank of Canada, and Banco Santander as bookrunners for the transaction.